Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Centre, International, Randomised, Vehicle Controlled, Parallel-Group, Double-Blinded Phase 2 Trial of BB2603 Topical Treatment in Subjects With Distal Subungual Onychomycosis (DSO) of the Toe nail

Trial Profile

A Multi-Centre, International, Randomised, Vehicle Controlled, Parallel-Group, Double-Blinded Phase 2 Trial of BB2603 Topical Treatment in Subjects With Distal Subungual Onychomycosis (DSO) of the Toe nail

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Terbinafine (Primary) ; Alcohol; Polihexanide
  • Indications Onychomycosis
  • Focus Therapeutic Use
  • Sponsors Blueberry Therapeutics

Most Recent Events

  • 13 Nov 2023 Primary endpoint has been met (Number of subjects with an Early Response for BB2603-10 versus vehicle), according to Blueberry Therapeutics.
  • 13 Nov 2023 Results published in the Blueberry Therapeutics Media Release.
  • 06 Jul 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top